drugset / Trial / NCT02081014
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
Phase 2
Completed
13 enrolled
Xeris Pharmaceuticals
Emissary International LLC · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedCrossoverSingle-blindTreatment
Summary
The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to moderate hypoglycemia, a complication of diabetes.
Timeline
- Start
- 2014-03
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glucagon | Peptide | 75 ug | Subcutaneous |
| Subject | Glucagon | Peptide | 150 ug | Subcutaneous |
| Subject | Glucagon | Peptide | 300 ug | Subcutaneous |